Dapagliflozin propranediol

Sold as Forxiga

C₂₁H₂₅ClO₆408.90 g/mol

(2S,3R,4R,5S,6R)-2-[4-Chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

Drag to rotate. Structure from PubChem CID 9887712.

Loading Wikipedia summary

Registration

Applicants: 1
Registrations: 2

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Astrazeneca Pharmaceuticals (Pty) Ltd	Forxiga	5, 10	460214, 460215	Not determined	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Forxiga 5 EACH TABLET CONTAINS DAPAGLIFLOZIN PROPRANEDIOL 5,0 mg	5Film-coated tablets	46021446/21.2/0214Approved 12 February 2026	Registered	Not determined	PI PIL
Forxiga 10 EACH TABLET CONTAINS DAPAGLIFLOZIN PROPRANEDIOL 10,0 mg	10Film-coated tablets	46021546/21.2/0215Approved 12 February 2026	Registered	Not determined	PI PIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Professional information (PI)For healthcare professionalsForxiga 5, Astrazeneca Pharmaceuticals (Pty) Ltd Patient information leaflet (PIL)For patients and carersForxiga 5, Astrazeneca Pharmaceuticals (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background